is jardiance a glp 1 drug Eli Lilly, Boehringer hit FDA roadblock in quest to repurpose for Type diabetes What are the dangers of

In clinical trials, GLP-1 drugs given in higher dosages than for diabetes showed the ability to stimulate double-digit-percentage weight loss in patients

Godknd fr behandling

Tapering off is when you slowly lower your dose or stretch out your dose frequency

The research is part of an ongoing series of studies examining the drugs potential side effects, which commonly include digestive issues such as nausea, bloating, and stomach discomfort

Pharmaceutical companies have been trying to produce small-molecule GLP-1 agonists that are shelf-stable and can be taken orallyfor instance, Pfizer and Eli Lilly have developed Danuglipron and Orforglipron, respectivelybut we know very little about how they work, said Ali Gler, a neuroscientist at the University of Virginia

27 Subsequently, they investigated a triple agonist capable of simultaneously targeting the GLP-1R, the GCGR, and the GIPR